Rocket Pharmaceuticals, Inc. financial data

Symbol
RCKT, RCKTW on Nasdaq
Industry
Pharmaceutical Preparations
Location
350 Fifth Avenue, Suite 7530, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Former names
INOTEK PHARMACEUTICALS CORP (to 12/22/2017)
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 993 % -7.42%
Debt-to-equity 13.2 % +6.1%
Return On Equity -53.1 % +4.67%
Return On Assets -46.9 % +5.31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.8M shares +12.8%
Common Stock, Shares, Outstanding 90.6M shares +12.7%
Entity Public Float 1.2B USD +86.2%
Common Stock, Value, Issued 906K USD +12.7%
Weighted Average Number of Shares Outstanding, Basic 93.5M shares +17.7%
Weighted Average Number of Shares Outstanding, Diluted 93.5M shares +17.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 185M USD +2.24%
General and Administrative Expense 79.6M USD +26.8%
Operating Income (Loss) -265M USD -8.55%
Nonoperating Income (Expense) 2.48M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -249M USD -5.1%
Earnings Per Share, Basic -2.85 USD/shares +14.2%
Earnings Per Share, Diluted -2.85 USD/shares +14.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.3M USD -45.4%
Cash, Cash Equivalents, and Short-term Investments 330M USD -8.25%
Assets, Current 345M USD +2.11%
Property, Plant and Equipment, Net 39.3M USD +28.6%
Operating Lease, Right-of-Use Asset 4.77M USD +2284%
Intangible Assets, Net (Excluding Goodwill) 25.2M USD -2.23%
Goodwill 39.2M USD 0%
Assets 499M USD -2.98%
Employee-related Liabilities, Current 4.19M USD -0.17%
Liabilities, Current 33M USD +5.61%
Operating Lease, Liability, Noncurrent 3.71M USD +1757%
Other Liabilities, Noncurrent 1.91M USD +1.65%
Liabilities 57.9M USD +3.69%
Accumulated Other Comprehensive Income (Loss), Net of Tax -135K USD -50%
Retained Earnings (Accumulated Deficit) -1.02B USD -32.3%
Stockholders' Equity Attributable to Parent 442M USD -3.79%
Liabilities and Equity 499M USD -2.98%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -56.9M USD +1.22%
Net Cash Provided by (Used in) Financing Activities 1.18M USD -93.5%
Net Cash Provided by (Used in) Investing Activities 35M USD
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 90.6M shares +12.7%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.6M USD -44.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 108M USD +18.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 4.78M USD +9.71%
Payments to Acquire Property, Plant, and Equipment 2.04M USD -32.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -249M USD -5.36%
Lessee, Operating Lease, Liability, to be Paid 6.52M USD +5.24%
Property, Plant and Equipment, Gross 55.1M USD +35%
Operating Lease, Liability, Current 1.06M USD +25.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.01M USD +86.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1M USD +25.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.74M USD -5.32%
Lessee, Operating Lease, Liability, to be Paid, Year Three 759K USD +39.3%
Deferred Tax Assets, Operating Loss Carryforwards 45.3M USD +34.4%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 522K USD +3.16%
Operating Lease, Payments 333K USD +27.6%
Additional Paid in Capital 1.46B USD +18.8%
Depreciation, Depletion and Amortization 1.7M USD +54.5%
Share-based Payment Arrangement, Expense 40.7M USD +21.1%
Interest Expense 1.88M USD +0.64%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%